Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Febrile Neutropenia 7 Neoplasms 5 Hematologic Neoplasms 3 Neutropenia 2 Fever 2 Urinary Bladder Neoplasms 1 Sepsis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Other Infectious Diseases 1 Leukemia, Myeloid, Acute 1 Emergencies 1

Interventions

Gemcitabine 157 Cisplatin 117 pembrolizumab 81 Cystectomy 46 Nivolumab 42 Carboplatin 42 Paclitaxel 41 Mitomycin 41 Docetaxel 39 atezolizumab 33 Magnetic Resonance Spectroscopy 33 Radiotherapy 31 durvalumab 30 avelumab 26 BCG Vaccine 26 Specimen Handling 25 Cystoscopy 24 enfortumab vedotin 23 Doxorubicin 23 Fluorouracil 20 Methotrexate 17 Vinblastine 16 Standard of Care 15 Ipilimumab 14 Filgrastim 14 5-aminolevulinic acid hexyl ester 14 Transurethral Resection of Bladder 13 Surgical Procedures, Operative 13 Sunitinib 13 Biopsy 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Urinary Bladder Neoplasms × Meropenem × Clear all

NCT05392634 2022-05-31

MACS

N.N. Petrov National Medical Research Center of Oncology

Phase 3 Unknown

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡